PriceTargets.com logo

Precigen - PGEN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.00
  • Forecasted Upside: 448.78%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$1.64 As of 01/27/2023 01:00 AM ET
▲ +0.02 (1.23%)

This chart shows the closing price for PGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Precigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PGEN

Analyst Price Target is $9.00
▲ +448.78% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Precigen in the last 3 months. The average price target is $9.00, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 448.78% upside from the last price of $1.64.

This chart shows the closing price for PGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Precigen. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/29/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/28/2023

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/18/2022Cantor FitzgeraldInitiated CoverageOverweight$7.00Low
11/10/2022JMP SecuritiesBoost TargetMarket Outperform$13.00 ➝ $14.00Low
8/9/2022HC WainwrightLower TargetBuy$10.00 ➝ $6.00Low
5/16/2022HC WainwrightReiterated RatingBuy$10.00Low
12/14/2021JMP SecuritiesReiterated RatingBuy$13.00Low
11/5/2021JMP SecuritiesReiterated RatingBuy$13.00Low
10/1/2021JMP SecuritiesReiterated RatingBuy$13.00Medium
8/10/2021HC WainwrightReiterated RatingBuy$10.00Low
5/11/2021HC WainwrightReiterated RatingBuyHigh
3/2/2021B. RileyBoost TargetBuy$10.00 ➝ $14.00High
2/25/2021Stifel NicolausInitiated CoverageBuy$13.00High
2/22/2021Wells Fargo & CompanyInitiated CoverageOverweight$14.00High
2/17/2021B. RileyInitiated CoverageBuy$10.00Medium
12/16/2020HC WainwrightBoost TargetBuy$8.00 ➝ $10.00High
6/24/2020HC WainwrightReiterated RatingBuy$8.00Low
6/10/2020JMP SecuritiesReiterated RatingOutperform$13.00High
5/8/2020HC WainwrightInitiated CoverageBuy$5.00Medium
8/12/2019Northland SecuritiesReiterated RatingHold$10.00Medium
8/9/2019Bank of AmericaLower TargetUnderperform$7.00 ➝ $6.00N/A
5/14/2019Northland SecuritiesReiterated RatingHold$7.00High
3/6/2019JMP SecuritiesReiterated RatingBuy$43.00Medium
3/1/2019Northland SecuritiesDowngradeOutperform ➝ Market PerformHigh
10/10/2018JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$42.00 ➝ $43.00Medium
7/17/2018Stifel NicolausInitiated CoverageBuy$72.00Low
7/16/2018Bank of AmericaDowngradeNeutral ➝ Underperform$12.00High
3/5/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ Neutral$22.00 ➝ $18.00High
3/2/2018Bank of AmericaLower TargetNeutral ➝ Neutral$21.00 ➝ $19.00Medium
3/2/2018Northland SecuritiesReiterated RatingBuy$17.00High
(Data available from 1/29/2018 forward)

News Sentiment Rating

1.06 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 6 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
9/1/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 5 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Precigen logo
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Read More

Today's Range

Now: $1.64
Low: $1.61
High: $1.70

50 Day Range

MA: $1.70
Low: $1.27
High: $2.19

52 Week Range

Now: $1.64
Low: $1.12
High: $2.90

Volume

4,320,856 shs

Average Volume

1,660,828 shs

Market Capitalization

$341.37 million

P/E Ratio

13.67

Dividend Yield

N/A

Beta

1.89

Frequently Asked Questions

What sell-side analysts currently cover shares of Precigen?

The following sell-side analysts have issued research reports on Precigen in the last year: Cantor Fitzgerald, HC Wainwright, JMP Securities, and StockNews.com.
View the latest analyst ratings for PGEN.

What is the current price target for Precigen?

3 Wall Street analysts have set twelve-month price targets for Precigen in the last year. Their average twelve-month price target is $9.00, suggesting a possible upside of 448.8%. JMP Securities has the highest price target set, predicting PGEN will reach $14.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $6.00 for Precigen in the next year.
View the latest price targets for PGEN.

What is the current consensus analyst rating for Precigen?

Precigen currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PGEN will outperform the market and that investors should add to their positions of Precigen.
View the latest ratings for PGEN.

What other companies compete with Precigen?

Other companies that are similar to Precigen include Tyra Biosciences, Prelude Therapeutics, Annexon, Generation Bio and Foghorn Therapeutics. Learn More about companies similar to Precigen.

How do I contact Precigen's investor relations team?

Precigen's physical mailing address is 20374 Seneca Meadows Parkway, Germantown MD, 20876. The biotechnology company's listed phone number is (301) 556-9900 and its investor relations email address is [email protected] The official website for Precigen is www.precigen.com. Learn More about contacing Precigen investor relations.